Announced Wed, 17 Jun · 08:37 IST
Glenmark US launches Methylene Blue Injection, targets USD 19M market
Compliance View source PDF
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.1%1-day move
₹2156.00
prior close
₹2128.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+1.1+1.2+1.7-0.1+2.3+1.7+0.9+1.3+1.2+5.5+3.5——
Up moveDown movePending
AI summary
Glenmark's US arm has launched Methylene Blue Injection USP, 50 mg/10 mL single-dose vial in the United States. The product is approved as equivalent to Provepharm's ProvayBlue Injection. Per IQVIA data for the 12 months ending April 2026, the addressable market had annual sales of about USD 19 million. The launch adds to Glenmark's US institutional medicine portfolio.
Likely market impact
Mildly positive - new product launch in US adds to institutional portfolio revenue, though the USD 19M target market is modest in size.